Melatonin increases overall survival of prostate cancer patients, finds study

Dr. Vladimir N. Anisimov from The N.N. Petrov National Medical Research Center of Oncology said, "Melatonin is the main hormone of the pineal gland."

Melatonin is most widely used in clinical practice to treat hormone-dependent tumors, and primarily in the combined treatment of breast cancer.

Some possible points of inhibition of tumor growth by melatonin included activation of T helper type 1; increased production of several cytokines; inhibition of angiogenesis; reduced expression of the VEGF receptors; activation of apoptosis in tumor cells; and a decrease in telomerase activity.

The results of the use of melatonin drugs in palliative treatment of patients with end-stage prostate cancer are shown.

Thus, the assessment of long-term results of wide clinical use of melatonin in the combined treatment of patients with prostate cancer of various risk groups is an urgent and relevant task.

The aim of the study was to improve the effectiveness of treatment of patients with prostate cancer by long-term use of melatonin drugs after a course of combined hormone-radiation treatment.

The Anisimov Research Team concluded in their Oncotarget Research Paper that "the results of our study are in agreement with the data on favorable antitumor effect melatonin treatment of patients with advanced cancer of various localization, mainly in the breast, uterus, colon, etc., .

Taking into consideration the optimistic conclusions obtained in our work, based on large clinical material, it is advisable to conduct prospective randomized studies with an assessment of survival rates in patients with PCa of various prognosis groups."